Evotec is a drug discovery alliance company providing drug discovery solutions to pharmaceutical and biotechnology companies.
Evotec is a drug discovery alliance and development partnership rapidly progressing innovative product approaches with pharmaceutical and biotechnology companies, academics, patient advocacy groups, and venture capitalists. Drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licencing of innovative drug candidates, and consulting arrangements.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 3, 2022 | Grant | €7.50M | 1 | German Federal Ministry of Education and Research (BMBF) | — | Detail |
Dec 16, 2021 | Grant | $18M | 1 | Bill & Melinda Gates Foundation | — | Detail |
Nov 4, 2021 | IPO | $435M | — | — | — | Detail |
Oct 19, 2020 | Grant | — | 1 | Bill & Melinda Gates Foundation | — | Detail |
Oct 13, 2020 | Post-IPO Equity | €250M | 2 | Mubadala | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Dec 1, 2022
Carrick Therapeutics
|
Series C | $60M | Biotechnology | — |
Nov 29, 2022
Cajal Neuroscience
|
Series A | $96M | Biotechnology | — |
May 3, 2022
Tubulis
|
Series B | €60M | Biotechnology | — |
Feb 16, 2022
Centauri Therapeutics
|
Series A | £24M | Biotechnology | — |
Feb 15, 2022
IMIDomics
|
Corporate Round | — | Biotechnology | Yes |
Investor Name | Lead Investor | Funding Round |
---|---|---|
German Federal Ministry of Education and Research (BMBF) | Yes | Grant |
Bill & Melinda Gates Foundation | Yes | Grant |
Mubadala | Yes | Post-IPO Equity |
CARB-X | Yes | Grant |
Biotechnology Value Fund | Yes | Series Unknown |
Novo Holdings | — | Post-IPO Equity |
3i Group | — | Series Unknown |
Gilde Healthcare | — | Series Unknown |
Omega Funds | — | Series Unknown |
Evotec has had 3 exits. Evotec most notable exits include Forge Therapeutics , Exscientia
Date | Company Name | Exit Type | Industry | |
---|---|---|---|---|
Jan 2, 2023 | Forge Therapeutics | M&A | Biotechnology | Detail |
Oct 1, 2021 | Exscientia | IPO | Artificial Intelligence | Detail |
Jul 12, 2002 | Sanofi | IPO | Health Care | Detail |
Evotec has acquired 15 organizations. Their most recent acquisition was Oxford Asymmetry International on Aug 1, 2000. They acquired Oxford Asymmetry International for 0.
Date
Company Name
|
Industry | Acquisition Type | Price | |
---|---|---|---|---|
Aug 1, 2000
Oxford Asymmetry International
|
Outsourcing | merge | — | Detail |
Mar 6, 2005
Evotec Neurosciences
|
Biopharma | acquisition | — | Detail |
Sep 19, 2007
Renovis
|
Innovation Management | acquisition | $ 152M | Detail |
Aug 31, 2009
Evotec (India) Private Ltd
|
Biotechnology | acquisition | — | Detail |
Jul 14, 2010
Develogen AG
|
Biotechnology | acquisition | — | Detail |